JP2015505483A - 医学画像を客観的に特徴付けるための方法および組成物 - Google Patents
医学画像を客観的に特徴付けるための方法および組成物 Download PDFInfo
- Publication number
- JP2015505483A JP2015505483A JP2014553500A JP2014553500A JP2015505483A JP 2015505483 A JP2015505483 A JP 2015505483A JP 2014553500 A JP2014553500 A JP 2014553500A JP 2014553500 A JP2014553500 A JP 2014553500A JP 2015505483 A JP2015505483 A JP 2015505483A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- enhancing agent
- autocorrelation
- contrast enhancing
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title abstract description 11
- 238000001228 spectrum Methods 0.000 claims abstract description 67
- 238000005311 autocorrelation function Methods 0.000 claims abstract description 44
- 230000002708 enhancing effect Effects 0.000 claims abstract description 41
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 25
- 230000008807 pathological lesion Effects 0.000 claims abstract description 16
- 230000008021 deposition Effects 0.000 claims abstract description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 57
- 239000002502 liposome Substances 0.000 claims description 57
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 34
- 239000002105 nanoparticle Substances 0.000 claims description 26
- 210000004556 brain Anatomy 0.000 claims description 18
- 235000012000 cholesterol Nutrition 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 13
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 13
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 13
- 239000013522 chelant Substances 0.000 claims description 10
- -1 liposomes Chemical compound 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 229960004359 iodixanol Drugs 0.000 claims description 4
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 4
- 229960001025 iohexol Drugs 0.000 claims description 4
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 4
- 230000009920 chelation Effects 0.000 claims 2
- CPKKNIYMTSBFIQ-UHFFFAOYSA-N cyclohexyl diphenyl phosphate Chemical group C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1CCCCC1 CPKKNIYMTSBFIQ-UHFFFAOYSA-N 0.000 claims 2
- 238000005538 encapsulation Methods 0.000 claims 2
- 150000002251 gadolinium compounds Chemical class 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 20
- 238000002591 computed tomography Methods 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 description 28
- 210000005166 vasculature Anatomy 0.000 description 26
- 210000004204 blood vessel Anatomy 0.000 description 24
- 230000002792 vascular Effects 0.000 description 22
- 238000005314 correlation function Methods 0.000 description 18
- 229910052688 Gadolinium Inorganic materials 0.000 description 14
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000009977 dual effect Effects 0.000 description 12
- 238000013425 morphometry Methods 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000003562 morphometric effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 3
- MLHUNYDEAXNWQZ-UHFFFAOYSA-N (4,4-diphenylcyclohexyl) dihydrogen phosphate Chemical group C1CC(OP(O)(=O)O)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 MLHUNYDEAXNWQZ-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 150000000921 Gadolinium Chemical class 0.000 description 2
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101000985214 Mus musculus 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 208000009443 Vascular Malformations Diseases 0.000 description 2
- MXZROTBGJUUXID-UHFFFAOYSA-I [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 Chemical compound [Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-I 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 2
- MXZROTBGJUUXID-UHFFFAOYSA-K gadobenic acid Chemical compound [H+].[H+].[Gd+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)C(C([O-])=O)COCC1=CC=CC=C1 MXZROTBGJUUXID-UHFFFAOYSA-K 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- PIZALBORPSCYJU-QSQMUHTISA-H gadofosveset Chemical compound O.[Na+].[Na+].[Na+].[Gd+3].C1CC(OP([O-])(=O)OC[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC(=O)[O-])N(CC([O-])=O)CC([O-])=O)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 PIZALBORPSCYJU-QSQMUHTISA-H 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5247—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/0035—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/44—Constructional features of apparatus for radiation diagnosis
- A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/12—Measuring magnetic properties of articles or specimens of solids or fluids
- G01R33/1269—Measuring magnetic properties of articles or specimens of solids or fluids of molecules labeled with magnetic beads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/12—Measuring magnetic properties of articles or specimens of solids or fluids
- G01R33/1276—Measuring magnetic properties of articles or specimens of solids or fluids of magnetic particles, e.g. imaging of magnetic nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0004—Industrial image inspection
- G06T7/0008—Industrial image inspection checking presence/absence
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/30—Determination of transform parameters for the alignment of images, i.e. image registration
- G06T7/32—Determination of transform parameters for the alignment of images, i.e. image registration using correlation-based methods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/30—Determination of transform parameters for the alignment of images, i.e. image registration
- G06T7/35—Determination of transform parameters for the alignment of images, i.e. image registration using statistical methods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10088—Magnetic resonance imaging [MRI]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30016—Brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- General Physics & Mathematics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Optics & Photonics (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Medicinal Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Quality & Reliability (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
本出願は、2012年1月20日に出願された米国仮特許出願第61/589,165号からの優先権を主張し、該米国仮特許出願は、参照によりその全体が本明細書に組み込まれる。
実施例
実施例1−二重Gdリポソームの調製
実施例2−マウスの脳血管系のMRI
実施例3−形態学的分析
実施例4−容積に基づく形態計測
実施例5−血管亀裂のシミュレーション
本出願は、2012年1月20日に出願された米国仮特許出願第61/589,165号からの優先権を主張し、該米国仮特許出願は、参照によりその全体が本明細書に組み込まれる。
実施例
実施例1−二重Gdリポソームの調製
実施例2−マウスの脳血管系のMRI
実施例3−形態学的分析
実施例4−容積に基づく形態計測
実施例5−血管亀裂のシミュレーション
Claims (22)
- 患者の病理学的病変を特徴付けるための方法であって、
前記患者にコントラスト強調剤を導入することと、
画像を取得するために、前記患者にMRIおよびCTのうちの少なくとも1つを受けさせることと、
少なくとも1つの3D自己相関スペクトルを取得するために、3D自己相関関数を前記画像の対象となるサブドメインに適用することと、
を含む、方法。 - 前記少なくとも1つの3D自己相関スペクトルを、前記病理学的病変に特徴的である既存の3D自己相関スペクトルと比較することをさらに含む、請求項1に記載の方法。
- 前記受けさせることは、前記患者にMRIを受けさせることを含む、請求項1に記載の方法。
- 前記コントラスト強調剤は、
リポソームであって、
リン脂質と、
ポリマーによって誘導体化されるリン脂質と、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、ガドリニウム化合物のカプセル化およびキレート化のうちの少なくとも1つを行う、請求項3に記載の方法。 - 前記コントラスト強調剤は、
リポソームであって、
DPPCと、
Gd−DTPA−BSAと、
コレステロールと、
mPEG2000−DSPEと、を含む、リポソームを含む、請求項3に記載の方法。 - 前記コントラスト強調剤は、ジフェニルシクロヘキシルホスフェート基を有するGdDTPAキレート誘導体を含む、請求項3に記載の方法。
- 前記受けさせることは、前記患者にCTを受けさせることを含む、請求項1に記載の方法。
- 前記コントラスト強調剤は、
リポソームであって、
リン脂質と、
ポリマーによって誘導体化されるリン脂質と、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、非放射性ヨウ素化コントラスト強調剤をカプセル化する、請求項7に記載の方法。 - 前記コントラスト強調剤は、
リポソームであって、
DPPCと、
mPEG2000−DSPEと、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、イオヘキソールおよびイオジキサノールのうちの少なくとも1つをカプセル化する、請求項7に記載の方法。 - 患者の脳のアミロイド斑沈着を検出するための方法であって、
前記患者にナノ粒子コントラスト強調剤を導入することと、
画像を取得するために、前記患者にMRIおよびCTのうちの少なくとも1つを受けさせることと、
少なくとも1つの3D自己相関スペクトルを取得するために、3D自己相関関数を前記画像の対象となるサブドメインに適用することと、
を含む、方法。 - 前記少なくとも1つの3D自己相関スペクトルを、脳のアミロイド斑沈着に特徴的である既存の3D自己相関スペクトルと比較することをさらに含む、請求項10に記載の方法。
- 前記受けさせることは、前記患者にMRIを受けさせることを含む、請求項10に記載の方法。
- 前記ナノ粒子コントラスト強調剤は、
リポソームであって、
リン脂質と、
ポリマーによって誘導体化されるリン脂質と、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、ガドリニウム化合物のカプセル化およびキレート化のうちの少なくとも1つを行う、請求項12に記載の方法。 - 前記ナノ粒子コントラスト強調剤は
リポソームであって、
DPPCと、
Gd−DTPA−BSAと、
コレステロールと、
mPEG2000−DSPEと、を含む、リポソームを含む、請求項12に記載の方法。 - 前記ナノ粒子コントラスト強調剤は、ジフェニルシクロヘキシルホスフェート基を有するGdDTPAキレート誘導体を含む、請求項12に記載の方法。
- 前記受けさせることは、前記患者にCTを受けさせることを含む、請求項10に記載の方法。
- 前記ナノ粒子コントラスト強調剤は、
リポソームであって
リン脂質と、
ポリマーによって誘導体化されるリン脂質と、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、非放射性ヨウ素化コントラスト強調剤をカプセル化する、請求項16に記載の方法。 - 前記ナノ粒子コントラスト強調剤は、
リポソームであって、
DPPCと、
mPEG2000−DSPEと、
コレステロールと、を含む、リポソームを含み、
前記リポソームは、イオヘキソールおよびイオジキサノールのうちの少なくとも1つをカプセル化する、請求項16に記載の方法。 - 患者のアルツハイマー病を診断するための方法であって、
前記患者にナノ粒子コントラスト強調剤を導入することであって、
リポソームであって、
DPPCと、
Gd−DTPA−BSAと、
コレステロールと、
mPEG2000−DSPEと、を含む、リポソームを含む、ナノ粒子コントラスト強調剤を導入することと、
画像を取得するために、前記患者にMRIを受けさせることと、
少なくとも1つの3D自己相関スペクトルを取得するために、3D自己相関関数を前記画像の対象となるサブドメインに適用することと、
を含む、方法。 - 前記少なくとも1つの3D自己相関スペクトルを、アルツハイマー病に特徴的である既存の3D自己相関スペクトルと比較することをさらに含む、請求項19に記載の方法。
- 前記DPPC、前記Gd−DTPA−BSA、前記コレステロール、および前記mPEG2000−DSPEのモル比は、約30:25:40:5である、請求項19に記載の方法。
- 前記リポソームは、約150nm未満の平均直径を有する、請求項19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261589165P | 2012-01-20 | 2012-01-20 | |
US61/589,165 | 2012-01-20 | ||
PCT/US2013/022336 WO2013110013A1 (en) | 2012-01-20 | 2013-01-20 | Methods and compositions for objectively characterizing medical images |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015505483A true JP2015505483A (ja) | 2015-02-23 |
JP6130401B2 JP6130401B2 (ja) | 2017-05-17 |
Family
ID=48797775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014553500A Active JP6130401B2 (ja) | 2012-01-20 | 2013-01-20 | 医学画像を客観的に特徴付けるための方法および組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10130326B2 (ja) |
EP (1) | EP2756459B1 (ja) |
JP (1) | JP6130401B2 (ja) |
KR (1) | KR102064398B1 (ja) |
CN (1) | CN104081416B (ja) |
AU (1) | AU2013209437B2 (ja) |
BR (1) | BR112014010879A2 (ja) |
CA (1) | CA2848994A1 (ja) |
ES (1) | ES2855165T3 (ja) |
HK (1) | HK1202176A1 (ja) |
MX (1) | MX366972B (ja) |
WO (1) | WO2013110013A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104144708B (zh) | 2011-04-06 | 2017-07-28 | 德克萨斯大学系统董事会 | 基于脂质的纳米粒子 |
CA2848994A1 (en) | 2012-01-20 | 2013-07-25 | Ananth Annapragada | Methods and compositions for objectively characterizing medical images |
EP3542828A1 (en) | 2014-10-08 | 2019-09-25 | Texas Children's Hospital | Mri imaging of amyloid plaque using liposomes |
US20200281500A1 (en) * | 2017-09-19 | 2020-09-10 | University Of Cincinnati | Systems and Methods for Detecting Small Physiological or Pathological Changes Using High Resolution Magnetic Resonance Imaging |
CN108961210B (zh) * | 2018-05-24 | 2021-08-31 | 上海集成电路研发中心有限公司 | 一种判断图像是否经过算法处理的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262339A1 (en) * | 2004-07-06 | 2008-10-23 | Garwood Michael G | Magnetic Resonance Imaging of Amyloid Plaque in the Brain |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204085A (en) | 1985-01-08 | 1993-04-20 | Mallinckrodt Medical, Inc. | Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents |
US4893082A (en) * | 1989-02-13 | 1990-01-09 | Letcher Iii John H | Noise suppression in magnetic resonance imaging |
AU2076895A (en) | 1994-03-28 | 1995-10-17 | Daiichi Pharmaceutical Co., Ltd. | Liposomes |
US6071532A (en) | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
US6067465A (en) * | 1997-11-26 | 2000-05-23 | General Electric Company | System and method for detecting and tracking reference position changes with linear phase shift in magnetic resonance imaging |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
EP1233752B1 (en) | 1999-11-30 | 2005-01-26 | The Arizona Board of Regents on behalf of The University of Arizona | Radiation sensitive liposomes |
US6463315B1 (en) * | 2000-01-26 | 2002-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of cerebral white matter for prognosis and diagnosis of neurological disorders |
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
WO2002094191A2 (en) * | 2001-05-23 | 2002-11-28 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
AU2003217950A1 (en) | 2002-03-05 | 2003-09-22 | Cleveland State University | Agglomerated particles for aerosol drug delivery |
EP2330113B1 (en) * | 2002-04-19 | 2016-06-29 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of Alzheimer's disease |
JP2005537841A (ja) * | 2002-09-04 | 2005-12-15 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 医療画像形成における表面の特徴付け |
US7605182B2 (en) | 2003-05-01 | 2009-10-20 | Aposense Ltd. | Compounds that selectively bind to membranes of apoptotic cells |
JP5137400B2 (ja) * | 2003-06-30 | 2013-02-06 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
CN101001569B (zh) * | 2004-02-06 | 2010-05-26 | 韦克福里斯特大学健康科学院 | 评估组织特性和检测病人整体心脏损害的系统 |
US20100031378A1 (en) * | 2008-08-04 | 2010-02-04 | Edwards Joel A | Novel gene disruptions, compositions and methods relating thereto |
US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
US7713517B2 (en) | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
US20080286202A1 (en) * | 2004-07-02 | 2008-11-20 | University Of Pittsburgh | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition |
DE602005025659D1 (ja) | 2004-09-23 | 2011-02-10 | Guerbet Sa | |
CN101189641B (zh) * | 2005-05-12 | 2012-05-02 | 布雷克成像有限公司 | 编码数字图像的像素或体素的方法及处理数字图像的方法 |
US20070160658A1 (en) | 2005-10-20 | 2007-07-12 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
EP1780672A1 (en) * | 2005-10-25 | 2007-05-02 | Bracco Imaging, S.P.A. | Method of registering images, algorithm for carrying out the method of registering images, a program for registering images using the said algorithm and a method of treating biomedical images to reduce imaging artefacts caused by object movement |
US20090123047A1 (en) * | 2007-03-21 | 2009-05-14 | Yfantis Spyros A | Method and system for characterizing prostate images |
EP1982733A1 (en) * | 2007-04-17 | 2008-10-22 | Bayer Schering Pharma Aktiengesellschaft | Use of a contrast agent for magnetic resonance imaging of endoleaks |
US20110311457A1 (en) * | 2007-07-26 | 2011-12-22 | Nanoscan Imaging, Llc | Methods for imaging vascular inflammation using improved nanoparticle contrast agents |
WO2009073236A1 (en) | 2007-12-05 | 2009-06-11 | Marval Biosciences, Inc. | Nano-scale contrast agents and methods of use |
US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
CA2711503A1 (en) | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
ITMI20081052A1 (it) | 2008-06-10 | 2009-12-11 | Univ Milano Bicocca | Liposomi in grado di legare efficacemente il peptide beta-amiloide |
US20090311191A1 (en) | 2008-06-13 | 2009-12-17 | Ananth Annapragada | Imaging of atherosclerotic plaques using liposomal imaging agents |
WO2010017094A2 (en) | 2008-07-31 | 2010-02-11 | The General Hospital Corporation | CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
EP2410990A4 (en) * | 2009-03-19 | 2015-05-20 | Marval Biosciences Inc | COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING |
JP5665040B2 (ja) * | 2009-09-10 | 2015-02-04 | 学校法人上智学院 | 変位計測方法及び装置、並びに、超音波診断装置 |
EP2501696B1 (en) * | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
US8679009B2 (en) * | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
DK2582674T3 (en) | 2010-06-16 | 2014-12-15 | Cymabay Therapeutics Inc | GPR120 receptor agonists and uses thereof. |
US8658614B2 (en) * | 2010-08-13 | 2014-02-25 | The University of Texas Health Science Center | Aptamer-containing compositions and methods for targeting E-selectin |
EP2680822B1 (en) | 2011-03-02 | 2022-02-23 | Sensulin, LLC | Vesicle compositions |
CN104144708B (zh) | 2011-04-06 | 2017-07-28 | 德克萨斯大学系统董事会 | 基于脂质的纳米粒子 |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
CA2848994A1 (en) | 2012-01-20 | 2013-07-25 | Ananth Annapragada | Methods and compositions for objectively characterizing medical images |
US9377472B2 (en) | 2012-04-30 | 2016-06-28 | Amoneta Diagnostics | Biological complex specific for Alzheimer's disease detection in vitro and use thereof |
CA2906035A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
EP3542828A1 (en) | 2014-10-08 | 2019-09-25 | Texas Children's Hospital | Mri imaging of amyloid plaque using liposomes |
-
2013
- 2013-01-20 CA CA2848994A patent/CA2848994A1/en not_active Abandoned
- 2013-01-20 BR BR112014010879A patent/BR112014010879A2/pt not_active Application Discontinuation
- 2013-01-20 MX MX2014003621A patent/MX366972B/es active IP Right Grant
- 2013-01-20 WO PCT/US2013/022336 patent/WO2013110013A1/en active Application Filing
- 2013-01-20 ES ES13738451T patent/ES2855165T3/es active Active
- 2013-01-20 CN CN201380003593.0A patent/CN104081416B/zh not_active Expired - Fee Related
- 2013-01-20 AU AU2013209437A patent/AU2013209437B2/en not_active Ceased
- 2013-01-20 US US13/745,813 patent/US10130326B2/en not_active Expired - Fee Related
- 2013-01-20 KR KR1020147013831A patent/KR102064398B1/ko active IP Right Grant
- 2013-01-20 EP EP13738451.7A patent/EP2756459B1/en active Active
- 2013-01-20 JP JP2014553500A patent/JP6130401B2/ja active Active
-
2015
- 2015-03-16 HK HK15102650.0A patent/HK1202176A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262339A1 (en) * | 2004-07-06 | 2008-10-23 | Garwood Michael G | Magnetic Resonance Imaging of Amyloid Plaque in the Brain |
Non-Patent Citations (2)
Title |
---|
JPN6016047066; B. Marty et al: 'About the origins of enhanced visualization of amyloid plaques on APP/PS1 mouse brain using GdDOTA p' Proc. Intl. Soc. Mag. Reson. Med. 17 , 200904, #878 * |
JPN6016047068; L. K. Hill et al: 'Micro-MR Angiography Using Gd-Loaded Micelles As Intravascular Contrast Agents In Mouse Models Amylo' Proc. Intl. Soc. Mag. Reson. Med. 17 , 200904, #3165 * |
Also Published As
Publication number | Publication date |
---|---|
EP2756459A1 (en) | 2014-07-23 |
KR102064398B1 (ko) | 2020-01-09 |
CA2848994A1 (en) | 2013-07-25 |
US10130326B2 (en) | 2018-11-20 |
KR20140114336A (ko) | 2014-09-26 |
AU2013209437B2 (en) | 2018-07-12 |
EP2756459B1 (en) | 2020-12-09 |
MX366972B (es) | 2019-08-01 |
HK1202176A1 (en) | 2015-09-18 |
ES2855165T3 (es) | 2021-09-23 |
EP2756459A4 (en) | 2014-08-27 |
US20130190605A1 (en) | 2013-07-25 |
JP6130401B2 (ja) | 2017-05-17 |
MX2014003621A (es) | 2014-08-22 |
CN104081416B (zh) | 2018-10-02 |
WO2013110013A1 (en) | 2013-07-25 |
WO2013110013A8 (en) | 2018-08-02 |
CN104081416A (zh) | 2014-10-01 |
AU2013209437A1 (en) | 2014-05-15 |
BR112014010879A2 (pt) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | MRI of atherosclerosis in clinical trials | |
JP6130401B2 (ja) | 医学画像を客観的に特徴付けるための方法および組成物 | |
US20090246138A1 (en) | Method of imaging metabolic function | |
Murayama et al. | Differentiating between central nervous system lymphoma and high-grade glioma using dynamic susceptibility contrast and dynamic contrast-enhanced MR imaging with histogram analysis | |
Langheinrich et al. | Evaluation of the middle cerebral artery occlusion techniques in the rat by in-vitro 3-dimensional micro-and nano computed tomography | |
Naganawa et al. | Relationship between parasagittal perivenous cysts and leakage of gadolinium-based contrast agents into the subarachnoid space around the cortical veins after intravenous administration | |
Haroun et al. | Arachnoid granulations in the cerebral dural sinuses as demonstrated by contrast-enhanced 3D magnetic resonance venography | |
US20210030301A1 (en) | System and Method for Detecting Small Blood-Tissue Barrier Disruption | |
Haroun | Utility of contrast-enhanced 3D turbo-flash MR angiography in evaluating the intracranial venous system | |
Zimmerman et al. | CT and MR: Diagnosis and evolution of head injury, stroke, and brain tumors. | |
Gasparotti et al. | Radiographic assessment of adult brachial plexus injuries | |
RU2554213C1 (ru) | Способ оценки риска ишемического нарушения мозгового кровообращения | |
Wippold II et al. | Neuroradiology: the surrogate of gross neuropathology | |
den Adel et al. | Self-gated CINE MRI for combined contrast-enhanced imaging and wall-stiffness measurements of murine aortic atherosclerotic lesions | |
WO2022047446A1 (en) | System and method for detecting the transport of substances across a biological barrier | |
Jambor et al. | Whole Brain Adiabatic T1rho and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings | |
Abdurakhimov et al. | ADVANCED MAGNETIC RESONANCE IMAGING (MRI) OF SOFT TISSUE TUMORS: TECHNIQUES AND APPLICATIONS | |
Khodjamova et al. | ADVANCED MAGNETIC RESONANCE IMAGING (MRI) OF SOFT TISSUE TUMORS: TECHNIQUES AND APPLICATIONS | |
Parashar et al. | Comparative Diagnostic Role of Computed Tomography Angiography (CTA) and Noncontrast Magnetic Resonance Angiography (NC-MRA) in Evaluation of Cerebrovascular Accidents. | |
Saba et al. | Near occlusion carotid artery: how to study it by using MDCTA: P 056 | |
Kim et al. | Analysis of Images According to the Fluid Velocity in Time-of-Flight Magnetic Resonance Angiography, and Contrast Enhancement Angiography | |
Ragheb et al. | Can DWI & ADC differentiate orbital lymphoma, non-specific orbital inflammation and orbital cellulitis? | |
Ku | Imaging in Neurooncology | |
Neuropathology | Neuroradiology: The Surrogate of | |
Trystram et al. | Three-dimensional dynamic magnetic resonance angiography for the evaluation of radiosurgically treated cerebral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151221 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170314 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170413 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6130401 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |